Syhrir Mauck/Istock via Getty Images
Axsome Therapeutics (shares (Nasdak: Nasdak:AxsmOn Monday, after the US Food and Drug Administration’s decision not to review the marketing request for Esreboxetine or AXS-14, to treat Fibromyalgia.
The FDA (FDA) said that after an initial evaluation, the new drug application
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1211291206/image_1211291206.jpg?io=getty-c-w750
Source link